MNKD Q4 2024 Earnings — MannKind Corporation Revenue & Financial Results | Market Cap Arena

MNKDMannKind Corporation

$813M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+31.3% YoY

Gross Profit

$57M74.5% margin

Operating Income

$26M34.5% margin

Net Income

$7M9.7% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+9.6%

Cash Flow

Operating Cash Flow

$23M

Free Cash Flow

$20M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$394M

Total Liabilities

$473M

Stockholders' Equity

-$79M

Cash & Equivalents

$46M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$58M	+31.3%
Gross Profit	$57M	$40M	+41.5%
Operating Income	$26M	$8M	+237.2%
Net Income	$7M	$1M	+429.8%

Revenue Segments

Royalty

$75M55%

Product

$63M45%